Clinical Trial Update: Safety and Efficiency of Linagliptin (Trajenta) in the Setting of Internal Medicine Department [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating safety and efficacy of linagliptin (Trajenta) in type 2 diabetes patients, with unknown overall status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Trajenta (linagliptin)

Snippet

Sponsor: Rabin Medical Center | Conditions: DM2 | Phase 3 | Status: UNKNOWN